• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

上尿路尿路上皮癌的保留肾手术:输尿管癌手术治疗的范式转变

Kidney sparing surgery in upper tract urothelial carcinoma: paradigm change in surgical treatment for ureter cancer.

作者信息

Kim Dongsu, You Dalsan, Jeong In Gab, Hong Jun Hyuk, Ahn Hanjong, Hong Bumsik

机构信息

Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, 43 Gil 88, Olympic-Road, Songpa-Gu, 05505, Seoul, Republic of Korea.

出版信息

J Cancer Res Clin Oncol. 2023 Nov;149(15):13717-13725. doi: 10.1007/s00432-023-05207-x. Epub 2023 Jul 31.

DOI:10.1007/s00432-023-05207-x
PMID:37522922
Abstract

PURPOSE

To extend the indications of kidney-sparing surgery (KSS) for ureter cancer by comparing the oncological outcomes between patients with upper tract urothelial carcinoma (UTUC) who underwent radical nephroureterectomy (RNU) or KSS.

METHODS

We retrospectively reviewed 708 patients with UTUC who underwent RNU (N = 646) or KSS (N = 62) between 2011 and 2019 to analyze the oncologic outcomes and prognostic factors. Subgroup analyses were performed for patients with unifocal ureteral urothelial carcinoma (UC).

RESULTS

No significant difference was observed in the overall survival (OS) or cancer-specific survival (CSS) between RNU and KSS (distal ureterectomy with reimplantation (N = 33), ureterectomy with ileal ureter (N = 14), ureteroscopic tumor resection (N = 10), and ureterectomy with ureteroureterostomy (N = 5)). Among 269 (38.0%) patients with unifocal ureteral UC, 219 and 50 patients underwent RNU and KSS, respectively. OS and CSS were not significantly different between these two groups. Pathologic stage was a significant risk factor in multivariate analysis (hazard ratio = 2.621; p = 0.000). Among 646 RNU patients, 219 (33.9%) had unifocal ureteral UC, 40 (18.3%) with low-grade tumors. Among these, 13 (5.9%) patients with unifocal, low-grade and small (< 2 cm) tumors received nephroureterectomy.

CONCLUSION

Kidney-sparing surgery should be regarded as an important alternative to RNU for patients with unifocal ureteral UC thought to have noninvasive disease to preserve renal function and reduce overtreatment.

摘要

目的

通过比较接受根治性肾输尿管切除术(RNU)或保留肾单位手术(KSS)的上尿路尿路上皮癌(UTUC)患者的肿瘤学结局,扩大保留肾单位手术(KSS)治疗输尿管癌的适应证。

方法

我们回顾性分析了2011年至2019年间接受RNU(N = 646)或KSS(N = 62)的708例UTUC患者,以分析肿瘤学结局和预后因素。对单灶性输尿管尿路上皮癌(UC)患者进行亚组分析。

结果

RNU组和KSS组(输尿管远端切除术加再植术(N = 33)、回肠代输尿管输尿管切除术(N = 14)、输尿管镜肿瘤切除术(N = 10)和输尿管输尿管吻合术输尿管切除术(N = 5))的总生存期(OS)或癌症特异性生存期(CSS)无显著差异。在269例(38.0%)单灶性输尿管UC患者中,分别有219例和50例接受了RNU和KSS。两组的OS和CSS无显著差异。病理分期在多因素分析中是一个显著的危险因素(风险比=2.621;p = 0.000)。在646例RNU患者中,219例(33.9%)患有单灶性输尿管UC,其中40例(18.3%)为低级别肿瘤。其中,13例(5.9%)单灶、低级别且肿瘤较小(<2 cm)的患者接受了肾输尿管切除术。

结论

对于被认为患有非侵袭性疾病的单灶性输尿管UC患者,保留肾单位手术应被视为RNU的重要替代方案,以保留肾功能并减少过度治疗。

相似文献

1
Kidney sparing surgery in upper tract urothelial carcinoma: paradigm change in surgical treatment for ureter cancer.上尿路尿路上皮癌的保留肾手术:输尿管癌手术治疗的范式转变
J Cancer Res Clin Oncol. 2023 Nov;149(15):13717-13725. doi: 10.1007/s00432-023-05207-x. Epub 2023 Jul 31.
2
Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel.保留肾单位手术与根治性肾输尿管切除术治疗上尿路上皮癌的肿瘤学结局:EAU 非肌肉浸润性膀胱癌指南小组的系统评价。
Eur Urol. 2016 Dec;70(6):1052-1068. doi: 10.1016/j.eururo.2016.07.014. Epub 2016 Jul 28.
3
Endoscopic intervention versus radical nephroureterectomy for the management of localized upper urinary tract urothelial carcinoma: a systematic review and meta-analysis of comparative studies.内镜介入与根治性肾输尿管切除术治疗局限性上尿路上皮癌的比较:系统评价和荟萃分析。
World J Urol. 2024 May 14;42(1):318. doi: 10.1007/s00345-024-05032-y.
4
A systematic review and meta-analysis of oncological and renal function outcomes obtained after segmental ureterectomy versus radical nephroureterectomy for upper tract urothelial carcinoma.对上尿路尿路上皮癌行节段性输尿管切除术与根治性肾输尿管切除术术后肿瘤学及肾功能结局的系统评价和荟萃分析。
Eur J Surg Oncol. 2016 Nov;42(11):1625-1635. doi: 10.1016/j.ejso.2016.08.008. Epub 2016 Aug 25.
5
Comparison of the oncological and functional outcomes among patients with high-risk upper tract urothelial cancer undergoing segmental ureterectomy based on tumour location.根据肿瘤位置接受节段性输尿管切除术的高危上尿路尿路上皮癌患者的肿瘤学和功能结局比较。
BJUI Compass. 2025 Jun 19;6(6):e70046. doi: 10.1002/bco2.70046. eCollection 2025 Jun.
6
Benefit and Harms of Radical Nephroureterectomy as Part of a Multimodal Treatment Strategy for Upper Tract Urothelial Carcinoma Patients Presenting with Clinical Evidence of Regional Lymph Node Metastasis: A Systematic Review and Meta-analysis by the European Association of Urology Guidelines.根治性肾输尿管切除术作为多模式治疗策略一部分对出现区域淋巴结转移临床证据的上尿路尿路上皮癌患者的获益与危害:欧洲泌尿外科学会指南的系统评价和荟萃分析
Eur Urol Oncol. 2025 Jun;8(3):841-852. doi: 10.1016/j.euo.2024.12.009. Epub 2025 Jan 7.
7
Comparative efficacy of kidney-sparing surgery versus radical nephroureterectomy for high-risk middle-lower ureteral urothelial carcinoma: a retrospective analysis.保留肾单位手术与根治性肾输尿管切除术治疗高危中下段输尿管尿路上皮癌的疗效比较:一项回顾性分析
Int Urol Nephrol. 2025 Jun 22. doi: 10.1007/s11255-025-04618-8.
8
Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review.经输尿管镜和经皮处理上尿路尿路上皮癌(UTUC):系统综述。
BJU Int. 2012 Sep;110(5):614-28. doi: 10.1111/j.1464-410X.2012.11068.x. Epub 2012 Apr 3.
9
Diagnosis and kidney-sparing treatments for upper tract urothelial carcinoma: state of the art.上尿路尿路上皮癌的诊断与保留肾单位治疗:现状
Minerva Urol Nefrol. 2018 Jun;70(3):242-251. doi: 10.23736/S0393-2249.18.03058-8. Epub 2018 Feb 1.
10
The long-term outcome of nephron-sparing surgery versus radical nephroureterectomy for organ-localized upper urinary tract urothelial carcinoma: a population-based study of 1969 patients.保肾手术与根治性肾输尿管切除术治疗局限性上尿路尿路上皮癌的长期疗效:1969 例患者的基于人群研究。
J Cancer Res Clin Oncol. 2023 Nov;149(16):14869-14878. doi: 10.1007/s00432-023-05264-2. Epub 2023 Aug 20.

引用本文的文献

1
Kidney sparing surgery versus radical nephroureterectomy in upper tract urothelial carcinoma: a meta-analysis and systematic review.上尿路尿路上皮癌保留肾手术与根治性肾输尿管切除术的Meta分析和系统评价
Front Oncol. 2025 Apr 2;15:1448079. doi: 10.3389/fonc.2025.1448079. eCollection 2025.
2
The Long-Term Functional and Oncologic Outcomes of Kidney-Sparing Surgery in Upper Tract Urothelial Carcinoma.上尿路尿路上皮癌保留肾单位手术的长期功能及肿瘤学结局
Ann Surg Oncol. 2025 Feb;32(2):1354-1363. doi: 10.1245/s10434-024-16523-y. Epub 2024 Nov 16.

本文引用的文献

1
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update.欧洲泌尿外科学会上尿路尿路上皮癌指南:2023 年更新版。
Eur Urol. 2023 Jul;84(1):49-64. doi: 10.1016/j.eururo.2023.03.013. Epub 2023 Mar 24.
2
Concomitant Bladder Tumor Is a Risk Factor for Bladder Recurrence but Not Upper Tract.同时性膀胱肿瘤是膀胱复发的危险因素,但不是上尿路的危险因素。
Curr Oncol. 2022 Nov 28;29(12):9284-9293. doi: 10.3390/curroncol29120727.
3
Kidney-sparing surgery for distal high-risk ureteral carcinoma: Clinical efficacy and preliminary experiences in 22 patients.
保肾手术治疗高危远端输尿管癌 22 例临床疗效及初步经验
Cancer Med. 2023 Apr;12(7):7835-7843. doi: 10.1002/cam4.5544. Epub 2022 Dec 19.
4
Changes in renal function after nephroureterectomy for upper urinary tract carcinoma: analysis of a large multicenter cohort (Radical Nephroureterectomy Outcomes (RaNeO) Research Consortium).肾输尿管切除术治疗上尿路尿路上皮癌术后肾功能变化:一项大型多中心队列研究(根治性肾输尿管切除术结果(RaNeO)研究联盟)。
World J Urol. 2022 Nov;40(11):2771-2779. doi: 10.1007/s00345-022-04156-3. Epub 2022 Oct 6.
5
A Systematic Review and Meta-Analysis of Prognostic Nomograms After UTUC Surgery.上尿路尿路上皮癌手术后预后列线图的系统评价与Meta分析
Front Oncol. 2022 Jul 1;12:907975. doi: 10.3389/fonc.2022.907975. eCollection 2022.
6
Survival and Long-term Effects of Kidney-sparing Surgery Versus Radical Nephroureterectomy on Kidney Function in Patients with Upper Urinary Tract Urothelial Carcinoma.保留肾单位手术与根治性肾输尿管切除术对上尿路尿路上皮癌患者肾功能的生存及长期影响
Eur Urol Open Sci. 2022 May 2;40:104-111. doi: 10.1016/j.euros.2022.04.007. eCollection 2022 Jun.
7
Incidence and Survival Rates of Contemporary Patients with Invasive Upper Tract Urothelial Carcinoma.当代浸润性上尿路上皮癌患者的发病率和生存率。
Eur Urol Oncol. 2021 Oct;4(5):792-801. doi: 10.1016/j.euo.2020.11.005. Epub 2020 Dec 5.
8
Perioperative complications and adverse sequelae of radical nephroureterectomy.根治性肾输尿管切除术的围手术期并发症及不良后遗症
Transl Androl Urol. 2020 Aug;9(4):1853-1859. doi: 10.21037/tau.2019.12.25.
9
Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial.在上尿路尿路上皮癌中的辅助化疗(POUT 试验):一项 3 期、开放标签、随机对照试验。
Lancet. 2020 Apr 18;395(10232):1268-1277. doi: 10.1016/S0140-6736(20)30415-3. Epub 2020 Mar 5.
10
Cancer statistics, 2020.癌症统计数据,2020 年。
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.